Literature DB >> 27402515

What Do We Know About Chagas Disease in the United States?

Susan P Montgomery1, Monica E Parise1, Ellen M Dotson1, Stephanie R Bialek1.   

Abstract

Chagas disease, caused by the parasite Trypanosoma cruzi, affects more than 5 million people worldwide leading to serious heart and gastrointestinal disease in a proportion of chronically infected patients. Important modes of transmission include vector-borne, congenital, and via blood transfusion or organ transplant from an infected donor. Vector-borne transmission of Chagas disease occurs in the Americas, including the southern half of North America, where the specific vector insects (triatomines), T. cruzi, and infected reservoir mammalian hosts are found. In the United States, there are estimated to be at least 300,000 cases of chronic Chagas disease among people originally from countries of Latin America where Chagas disease is endemic. Fewer than 30 cases of locally acquired infection have been documented in the United States, although a sylvatic transmission cycle has been known to exist in this country for at least a century. Studies defining risks for locally acquired infection and effective prevention strategies are needed to help prevent domestic transmission of T. cruzi To help address Chagas disease in the United States, improved health-care provider awareness and knowledge, better tools for screening and diagnosing patients, and wider availability of treatment drugs are needed. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Year:  2016        PMID: 27402515      PMCID: PMC5154432          DOI: 10.4269/ajtmh.16-0213

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  15 in total

1.  The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors.

Authors:  Paul T Cantey; Susan L Stramer; Rebecca L Townsend; Hany Kamel; Karen Ofafa; Charles W Todd; Mary Currier; Sheryl Hand; Wendy Varnado; Ellen Dotson; Chris Hall; Pamela L Jett; Susan P Montgomery
Journal:  Transfusion       Date:  2012-03-08       Impact factor: 3.157

2.  [Observations on defecation and contact feeding time of several South American Triatoma].

Authors:  E DIAS
Journal:  Mem Inst Oswaldo Cruz       Date:  1956-06       Impact factor: 2.743

3.  The biology and vector capability of Triatoma sanguisuga texana usinger and Triatoma gerstaeckeri (Stål) compared with Rhodnius prolixus (Stål) (Hemiptera: Triatominae).

Authors:  W F Pippin
Journal:  J Med Entomol       Date:  1970-01       Impact factor: 2.278

Review 4.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

5.  Feeding and defecation behavior of Triatoma rubida (Uhler, 1894) (Hemiptera: Reduviidae) under laboratory conditions, and its potential role as a vector of Chagas disease in Arizona, USA.

Authors:  Carolina E Reisenman; Teresa Gregory; Pablo G Guerenstein; John G Hildebrand
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

Review 6.  Trypanosoma cruzi and Chagas' Disease in the United States.

Authors:  Caryn Bern; Sonia Kjos; Michael J Yabsley; Susan P Montgomery
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

7.  Physician awareness of Chagas disease, USA.

Authors:  Kelly K Stimpert; Susan P Montgomery
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

8.  Triatoma rubrovaria (Blanchard, 1843) (Hemiptera-Reduviidae-Triatominae) III: patterns of feeding, defecation and resistance to starvation.

Authors:  Carlos Eduardo Almeida; Cesar Nascimento Francischetti; Raquel S Pacheco; Jane Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2003-07-18       Impact factor: 2.743

9.  An estimate of the burden of Chagas disease in the United States.

Authors:  Caryn Bern; Susan P Montgomery
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

10.  Potential novel risk factors for autochthonous and sylvatic transmission of human Chagas disease in the United States.

Authors:  Melissa N Garcia; Peter J Hotez; Kristy O Murray
Journal:  Parasit Vectors       Date:  2014-07-04       Impact factor: 3.876

View more
  25 in total

1.  Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.

Authors:  Bala C Chenna; Linfeng Li; Drake M Mellott; Xiang Zhai; Jair L Siqueira-Neto; Claudia Calvet Alvarez; Jean A Bernatchez; Emily Desormeaux; Elizabeth Alvarez Hernandez; Jana Gomez; James H McKerrow; Jorge Cruz-Reyes; Thomas D Meek
Journal:  J Med Chem       Date:  2020-03-17       Impact factor: 7.446

2.  Evaluation of the Performance of Ortho T. cruzi ELISA Test System for the Detection of Antibodies to Trypanosoma cruzi.

Authors:  Hilda N Rivera; Isabel McAuliffe; TaLesa Aderohunmu; Ryan E Wiegand; Susan P Montgomery; Richard S Bradbury; Sukwan Handali
Journal:  J Clin Microbiol       Date:  2022-07-12       Impact factor: 11.677

Review 3.  Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States.

Authors:  Amanda Irish; Jeffrey D Whitman; Eva H Clark; Rachel Marcus; Caryn Bern
Journal:  Emerg Infect Dis       Date:  2022-07       Impact factor: 16.126

Review 4.  Signal peptide peptidase: a potential therapeutic target for parasitic and viral infections.

Authors:  Christopher Schwake; Michael Hyon; Athar H Chishti
Journal:  Expert Opin Ther Targets       Date:  2022-03-07       Impact factor: 6.797

5.  Trypanosoma cruzi diversity in naturally infected nonhuman primates in Louisiana assessed by deep sequencing of the mini-exon gene.

Authors:  Claudia Herrera; Alicia Majeau; Peter Didier; Kathrine P Falkenstein; Eric Dumonteil
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-05-01       Impact factor: 2.184

6.  Physician Knowledge, Attitudes, and Practices Related to Chagas Disease in Tabasco, Mexico.

Authors:  Brandon A Berger; Allison H Bartlett; Ricardo Jiménez-Hernández; Esmelin Trinidad Vázquez; Norma Galindo-Sevilla
Journal:  Am J Trop Med Hyg       Date:  2018-04-19       Impact factor: 2.345

7.  Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.

Authors:  Xiaomo Li; Sijia Yi; Débora B Scariot; Santiago J Martinez; Ben A Falk; Cheryl L Olson; Patricia S Romano; Evan A Scott; David M Engman
Journal:  JCI Insight       Date:  2021-05-10

8.  Prevalence and Seroprevalence of Trypanosoma cruzi Infection in a Military Population in Texas.

Authors:  Bryant J Webber; Mary T Pawlak; Sandra Valtier; Candelaria C Daniels; Charla C Tully; Edward J Wozniak; Walter D Roachell; Francisco X Sanchez; Audra A Blasi; Thomas L Cropper
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

9.  Regarding Perspective Piece from July 2016 "What Do We Know About Chagas Disease in the United States?"

Authors:  Kenrad E Nelson; Paul M Ness; David A Leiby
Journal:  Am J Trop Med Hyg       Date:  2017-03       Impact factor: 2.345

10.  The Hookworm Blues: We Still Got 'em.

Authors:  John W Sanders; Karen A Goraleski
Journal:  Am J Trop Med Hyg       Date:  2017-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.